| abstract |
The present invention provides a mutant androgen receptor (AR) useful for screening an agent for the prophylaxis/treatment of androgen-independent cancer and the like, DNA encoding the AR and the like. It also provides a method of producing a mutant AR expressing cancer cell line in vitro, a method of screening for an anti-antiandrogen drug using the mutant AR expressing cancer cell line obtained by this method, a method of classifying anti-androgen drugs, a cocktail therapy agent comprising a combination of anti-androgen drugs classified by this method and the like. |